Cumberland Pharmaceuticals (NASDAQ:CPIX) has announced the launch of a new ready-to-use Caldolor product, following previous FDA approval for a new delivery method.
The ibuprofen product now comes in a ready-to-use bag that can be administered without dilution, the company says. the bag contains 800 mg of ibuprofen in a 200 mL patented low-sodium formulation for injection.
“We have been encouraged by the significant number of physicians who have incorporated Caldolor into their pain management regimens as a way to combat the negative effects of opioid use,” says CEO A.J. Kazimi.
Shares are up 3% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.